KIF3C has also been identified as a factor that can impede glioma growth by modulating the PI3K/AKT/mTOR pathway, thereby extending the survival of glioma patients, and offering a prospective target for glioma treatment [9]. This evidence concerns the gene AKT1 and central nervous system cancer.